Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/289853 
Year of Publication: 
2024
Series/Report no.: 
WWZ Working Paper No. 2024/02
Publisher: 
University of Basel, Center of Business and Economics (WWZ), Basel
Abstract: 
Real-world data (RWD) are an increasingly important input into the pharmaceutical R&D process as shown by countries like the USA or Finland. As the availability of and access to Swiss RWD is rather limited, the question arises whether this creates a burden for pharmaceutical R&D in Switzerland. We build on the economics of data and ideas as well as the home-market effect to analyze the importance of local RWD in the three stages of pharmaceutical R&D (pre-clinical, clinical, and post-approval research) as well as in the field of personalized medicine. We find qualitative support for a home-market effect and conclude that there is an urgent need to improve the current RWD situation in Switzerland, from the perspective of both Swiss patients and pharmaceutical R&D in Switzerland.
Subjects: 
Patient Data
Real-World Data
Pharmaceutical R&D
Data and Innovation
Home-Market Effects
International Trade
Location of R&D
JEL: 
F1
O3
L65
Persistent Identifier of the first edition: 
Document Type: 
Working Paper

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.